Why the Mesoblast (ASX:MSB) share price jumped 14% higher today

The Mesoblast limited (ASX:MSB) share price is the best performer on the ASX 200 on Monday. Here’s why it is charging higher…

| More on:
child in a superman outfit indicating a surge in share price

Image source: Getty Images

The best performer on the S&P/ASX 200 Index (ASX: XJO) on Monday has been the Mesoblast limited (ASX: MSB) share price.

In afternoon trade the biotechnology company’s shares are up a sizeable 11% to $3.54.

At one stage the Mesoblast share price was up as much as 14.5% to $3.65.

Why is the Mesoblast share price surging higher?

Investors appear to have been buying Mesoblast’s shares on Monday on the belief that they were oversold on Friday following the release of a disappointing announcement.

That announcement revealed that the U.S. FDA has not approved its remestemcel-L (RYONCIL) treatment for paediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

This came as a big surprise to the market because in August the Oncologic Drugs Advisory Committee (ODAC) of the FDA voted 9:1 in favour that the available data support the efficacy of remestemcel-L in pediatric patients with SR-aGVHD.

It isn’t often that the FDA goes against the ODAC’s vote, but this is what happened last week.

However, it isn’t the end of the road. The regulatory body has recommended that Mesoblast conduct at least one additional randomised, controlled study in adults or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.

In addition to this, as there are currently no approved treatments for the life-threatening condition in children under 12, Mesoblast is urgently requesting a Type A meeting with the FDA. This meeting is expected within 30 days and will discuss a potential accelerated approval with a post-approval condition for an additional study.

Judging by the Mesoblast share price performance today, some investors appear optimistic the company will be able to convince the FDA to approve the treatment at this meeting.

Should you buy the dip?

Mesoblast is an exciting company, but I would suggest investors keep their powder dry until a final decision is known.

Until then, I believe there are too many risks and not a sufficient reward for investors.

As a result, I think investors would be better off buying biotech giant CSL Limited (ASX: CSL) at this point.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Share Gainers

Why did the Dubber share price push 18% higher today?

Dubber shares have bounced from yearly lows.

Read more »

Two workers on site discuss the next stage of this civil engineering job, one points his hands upwards.
Share Gainers

Why did this ASX nickel share surge 23% today?

Investors keep rewarding ASX listed metals and mining companies in 2022.

Read more »

Share Gainers

Why BlueScope, Firefinch, Monash IVF, and South32 shares are pushing higher

These ASX shares are on form on Wednesday...

Read more »

Five happy miners standing next to each other.
Share Gainers

3 ASX mining shares surging more than 10% today

Metals and mining stocks continue to be rewarded in 2022

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop regarding the NRW share price
Share Gainers

Why these 2 ASX All Ordinaries shares are surging more than 20% today

Two ASX technology shares are leading the charge higher today.

Read more »

Rocket powering up and symbolising a rising share price.
Share Gainers

The Galileo Mining share price has rocketed 380% in a week. But this billionaire is still buying up big

The upside continues for the Galileo today.

Read more »

A laughing woman wearing a bright yellow suit, black glasses and a black hat spins dollar bills out of her hands signifying the big dividends paid by BHP
Share Gainers

Who wants to be a millionaire? If only you’d invested $10,000 in these ASX shares 10 years ago

You won’t believe how much you would have pocketed if you had bought these shares a decade ago.

Read more »

Rising share price chart.
Share Gainers

Why BlueScope, OFX, Pilbara Minerals, and Step One shares are pushing higher

These ASX shares are pushing higher...

Read more »